Epicutaneous Testing of Cosmetics for Skin Compatibility
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jan 16, 2017
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well different cosmetic products work on the skin and whether they cause any irritation or allergic reactions. Researchers want to ensure that new and reformulated cosmetics are safe for people with skin conditions like dermatitis. To do this, they will use patch tests, which involve placing small amounts of these products on the skin to see how it reacts.
If you are an adult over 18 years old and have a skin condition that requires a diagnostic patch test, you might be eligible to participate in this study. However, individuals with recent skin inflammation, those using certain medications like corticosteroids, or those who have had UV exposure on their back in the past month will not be able to join. Participants will help us understand how these cosmetic products affect the skin, and they will receive guidance on what to expect during the testing process. Your involvement could contribute to making cosmetics safer for everyone!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women older than 18 years old
- • Persons undergoing a diagnostic patch test for reason of a skin disease
- • Signed written informed consent
- Exclusion Criteria:
- • Acute skin inflammation and eczema on the back
- • Systemic corticosteroid and immunosuppressive therapy as well as UV exposure of the back within the last 4 weeks
- • Topical corticosteroids used on the back within the last two weeks
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Dagmar Simon, MD
Principal Investigator
Dept. of Dermatology, Inselspital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials